Emergent BioSolutions (EBS) News Today $6.94 +0.21 (+3.12%) As of 05/20/2025 03:58 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EBS Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Emergent BioSolutions Inc. (NYSE:EBS) Stock Position Cut by D. E. Shaw & Co. Inc.D. E. Shaw & Co. Inc. lessened its stake in Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 50.3% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 383,043 shares of the biopharmaceutical company's stocMay 21 at 4:03 AM | marketbeat.comCetera Investment Advisers Sells 107,236 Shares of Emergent BioSolutions Inc. (NYSE:EBS)Cetera Investment Advisers lessened its position in Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 27.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 277,247 shares of the biopharmaceutical company's stocMay 20 at 3:55 AM | marketbeat.comHC Wainwright Has Pessimistic Outlook of EBS Q2 EarningsEmergent BioSolutions Inc. (NYSE:EBS - Free Report) - HC Wainwright lowered their Q2 2025 earnings estimates for Emergent BioSolutions in a report issued on Thursday, May 15th. HC Wainwright analyst R. Selvaraju now forecasts that the biopharmaceutical company will post earnings of ($0.26) per shMay 20 at 1:49 AM | marketbeat.comNomura Holdings Inc. Trims Stock Position in Emergent BioSolutions Inc. (NYSE:EBS)Nomura Holdings Inc. lowered its stake in shares of Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 24.7% in the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 194,600 shares of the biopharmaceutical company's stock after selling 63,900 shares during theMay 19 at 5:17 AM | marketbeat.comMorse Asset Management Inc Invests $1.52 Million in Emergent BioSolutions Inc. (NYSE:EBS)Morse Asset Management Inc acquired a new position in shares of Emergent BioSolutions Inc. (NYSE:EBS - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 158,819 shares of the biopharmaceutical company's stock, valued at approMay 15, 2025 | marketbeat.comEmergent BioSolutions to Participate in Upcoming Investor ConferencesMay 14, 2025 | globenewswire.comCubist Systematic Strategies LLC Sells 132,107 Shares of Emergent BioSolutions Inc. (NYSE:EBS)Cubist Systematic Strategies LLC decreased its holdings in Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 40.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 198,373 shares of the biopharmaceutical company's stock after selling 132,1May 14, 2025 | marketbeat.comDimensional Fund Advisors LP Increases Stake in Emergent BioSolutions Inc. (NYSE:EBS)Dimensional Fund Advisors LP grew its stake in Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 67.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,104,058 shares of the biopharmaceutMay 12, 2025 | marketbeat.comDeerfield Management Company L.P. Series C Sells 61,584 Shares of Emergent BioSolutions Inc. (NYSE:EBS)Deerfield Management Company L.P. Series C reduced its position in Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 81.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,058 sMay 10, 2025 | marketbeat.comSchonfeld Strategic Advisors LLC Makes New $1.40 Million Investment in Emergent BioSolutions Inc. (NYSE:EBS)Schonfeld Strategic Advisors LLC bought a new stake in shares of Emergent BioSolutions Inc. (NYSE:EBS - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 145,912 shares of the biopharmaceutical comMay 9, 2025 | marketbeat.comEmergent biosolutions reaffirms 2025 revenue guidance of $750M-$850M amid turnaround progressMay 9, 2025 | msn.comBarclays PLC Acquires 55,215 Shares of Emergent BioSolutions Inc. (NYSE:EBS)Barclays PLC lifted its holdings in shares of Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 140.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 94,523 shares of the biopharmaceutical company's stock after purchaMay 8, 2025 | marketbeat.comEmergent BioSolutions Inc. (EBS) Q1 2025 Earnings Call TranscriptMay 7, 2025 | seekingalpha.comEmergent BioSolutions Reports First Quarter 2025 Financial ResultsMay 7, 2025 | globenewswire.comEmergent BioSolutions Stockholders Elect Directors at MeetingMay 6, 2025 | tipranks.comSusquehanna Fundamental Investments LLC Makes New Investment in Emergent BioSolutions Inc. (NYSE:EBS)Susquehanna Fundamental Investments LLC bought a new stake in Emergent BioSolutions Inc. (NYSE:EBS - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 98,731 shares of the biopharmaceutical company'May 5, 2025 | marketbeat.com92,691 Shares in Emergent BioSolutions Inc. (NYSE:EBS) Acquired by 683 Capital Management LLC683 Capital Management LLC acquired a new position in shares of Emergent BioSolutions Inc. (NYSE:EBS - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 92,691 shares of the biophaMay 4, 2025 | marketbeat.comEmergent BioSolutions Gets $65M Deal for Ontario Naloxone ProgramMay 2, 2025 | marketwatch.comEmergent BioSolutions (EBS) Projected to Post Quarterly Earnings on WednesdayEmergent BioSolutions (NYSE:EBS) will be releasing its Q1 2025 earnings after the market closes on Wednesday, May 7. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-7-emergent-biosolutions-inc-stock/)May 2, 2025 | marketbeat.comEmergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of HealthMay 1, 2025 | globenewswire.comMarshall Wace LLP Sells 1,165,943 Shares of Emergent BioSolutions Inc. (NYSE:EBS)Marshall Wace LLP reduced its holdings in Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 46.7% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 1,328,641 shares of the biopharmaceutical company'sApril 24, 2025 | marketbeat.comEmergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025April 22, 2025 | globenewswire.comJump Financial LLC Has $1.36 Million Stock Position in Emergent BioSolutions Inc. (NYSE:EBS)Jump Financial LLC boosted its stake in shares of Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 279.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 141,938 shares of the biopharmaceutical companApril 22, 2025 | marketbeat.comInvesco Ltd. Has $14.72 Million Stock Holdings in Emergent BioSolutions Inc. (NYSE:EBS)Invesco Ltd. boosted its position in shares of Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 70.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,539,907 shares of the biopharmaceutical company's stock after purchasing an additiApril 22, 2025 | marketbeat.comEmergent BioSolutions Inc. (NYSE:EBS) Shares Bought by Renaissance Technologies LLCRenaissance Technologies LLC grew its holdings in Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 26.8% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 665,847 shares of the biopharmaceutical company's stock after bApril 21, 2025 | marketbeat.comVanguard Group Inc. Sells 196,926 Shares of Emergent BioSolutions Inc. (NYSE:EBS)Vanguard Group Inc. lowered its position in shares of Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 5.8% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,200,700 shares of the biophApril 16, 2025 | marketbeat.comTrexquant Investment LP Has $6.71 Million Holdings in Emergent BioSolutions Inc. (NYSE:EBS)Trexquant Investment LP boosted its position in shares of Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 59.3% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 701,517 shares of the biopharmacApril 6, 2025 | marketbeat.comEmergent BioSolutions rises 11.8%April 2, 2025 | markets.businessinsider.comEmergent BioSolutions (NYSE:EBS) Given Buy Rating at HC WainwrightHC Wainwright restated a "buy" rating and set a $15.00 target price on shares of Emergent BioSolutions in a research report on Tuesday.April 2, 2025 | marketbeat.comEmergent BioSolutions (NYSE:EBS) to Repurchase $50.00 million in SharesEmergent BioSolutions (NYSE:EBS - Get Free Report) declared that its Board of Directors has authorized a stock buyback plan on Monday, March 31st, RTT News reports. The company plans to repurchase $50.00 million in outstanding shares. This repurchase authorization authorizes the biopharmaceutical company to purchase up to 19% of its shares through open market purchases. Shares repurchase plans are usually a sign that the company's board of directors believes its shares are undervalued.April 1, 2025 | marketbeat.comEmergent BioSolutions announces $50M stock repurchase programApril 1, 2025 | markets.businessinsider.comEmergent BioSolutions rises 9.0%April 1, 2025 | markets.businessinsider.comEmergent BioSolutions Announces Stock Repurchase ProgramMarch 31, 2025 | globenewswire.comAmerican Century Companies Inc. Increases Stake in Emergent BioSolutions Inc. (NYSE:EBS)American Century Companies Inc. grew its position in Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 23.4% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 2,137,712 shares of the biopharmaceutical company's stock after buying an additional 404,667 shaMarch 31, 2025 | marketbeat.comEmergent BioSolutions: I See Further Downside Ahead In This Value TrapMarch 26, 2025 | seekingalpha.comQ1 Earnings Forecast for EBS Issued By HC WainwrightEmergent BioSolutions Inc. (NYSE:EBS - Free Report) - Analysts at HC Wainwright issued their Q1 2026 earnings estimates for Emergent BioSolutions in a research note issued to investors on Friday, March 21st. HC Wainwright analyst R. Selvaraju forecasts that the biopharmaceutical company will postMarch 24, 2025 | marketbeat.comEmergent BioSolutions (NYSE:EBS) Receives "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $15.00 target price on shares of Emergent BioSolutions in a report on Friday.March 22, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Reduces Stock Position in Emergent BioSolutions Inc. (NYSE:EBS)Charles Schwab Investment Management Inc. lessened its holdings in Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 42.0% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,290,230 shares of the biopharmaceuticalMarch 22, 2025 | marketbeat.comEmergent BioSolutions sells Baltimore facility to SyngeneMarch 21, 2025 | investing.comExpert Outlook: Emergent BioSolutions Through The Eyes Of 5 AnalystsMarch 21, 2025 | benzinga.comEmergent Biosolutions’ Strategic Investments and Divestitures Justify Buy RatingMarch 21, 2025 | tipranks.comEmergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08March 20, 2025 | globenewswire.comHikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mgMarch 20, 2025 | globenewswire.comEmergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene InternationalMarch 19, 2025 | globenewswire.comEmergent BioSolutions announces $27M in incremental salesMarch 19, 2025 | markets.businessinsider.comEmergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure ProductsMarch 18, 2025 | globenewswire.comEmergent BioSolutions Inc. (NYSE:EBS) Shares Bought by Connor Clark & Lunn Investment Management Ltd.Connor Clark & Lunn Investment Management Ltd. grew its holdings in Emergent BioSolutions Inc. (NYSE:EBS - Free Report) by 8.3% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 902,332 shares of the biopharmaceutical companMarch 16, 2025 | marketbeat.comEmergent BioSolutions reinforces commitment to expanding access to NARCANMarch 13, 2025 | markets.businessinsider.comEmergent BioSolutions Inc. (NYSE:EBS) Director Sells $204,050.00 in StockEmergent BioSolutions Inc. (NYSE:EBS - Get Free Report) Director Neal Franklin Fowler sold 35,000 shares of the firm's stock in a transaction dated Wednesday, March 12th. The stock was sold at an average price of $5.83, for a total transaction of $204,050.00. Following the transaction, the director now owns 101,100 shares of the company's stock, valued at approximately $589,413. This represents a 25.72 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.March 13, 2025 | marketbeat.comEmergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness ProgramsMarch 13, 2025 | globenewswire.com Get Emergent BioSolutions News Delivered to You Automatically Sign up to receive the latest news and ratings for EBS and its competitors with MarketBeat's FREE daily newsletter. Email Address EBS Media Mentions By Week EBS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EBS News Sentiment▼0.310.65▲Average Medical News Sentiment EBS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EBS Articles This Week▼125▲EBS Articles Average Week Get Emergent BioSolutions News Delivered to You Automatically Sign up to receive the latest news and ratings for EBS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies CLDX News MNKD News NVAX News DVAX News INVA News OPK News GERN News RGLS News ZBIO News VSTM News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:EBS) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Emergent BioSolutions Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Emergent BioSolutions With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy EBS Stock Free EBS Stock Alerts